Henry Schein (HSIC) AI Stock Analysis

• Market Cap: $7.89B
• Dividend Yield: N/A
• Average Volume (3M): 1.65M
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.39
• Revenue Growth: 2.29%
• EPS Growth: 14.98%
• Country: US
• Employees: 25,000
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Distribution
• EPS (TTM): 1.10
• Shares Outstanding: 121,719,540
• 10 Day Avg. Volume: 1,799,027
• 30 Day Avg. Volume: 1,646,580
• PEG Ratio: -7.28
• Price to Book (P/B): 2.63
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 13.51
• Enterprise Value/Market Cap: 1.73
• Enterprise Value/Revenue: 1.07
• Enterprise Value/Gross Profit: 3.47
• Enterprise Value/Ebitda: 14.21
• 1Y Price Target: $74.90
• Price Target Upside: 15.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 61 Neutral
• Price Target: $68.00 ▲(4.89% Upside)

Henry Schein's overall stock score reflects stable financial performance and moderate valuation. The technical analysis indicates bearish momentum, which is a concern. The earnings call provided mixed sentiment, with strong growth in certain areas but challenges in margins and expenses. Corporate events, while significant, are already considered in the earnings analysis.

Positive Factors

E-commerce Launch

The coming launch of the new e-commerce site could position Schein well to deliver on its long-term goals.

Investments

Management spoke optimistically about recent investments like second-quarter promotional activities helping recapture incremental distribution business.

Partnership Benefits

The business starts to see some early benefits of its partnership with KKR and two other consulting firms.

Negative Factors

Customer Transition

Heartland Dental, the largest DSO in the U.S. and HSIC's biggest single customer, has recently fielded a 'Request for Solutions' and is considering moving the entirety of its consumables/equipment/services business away from HSIC.

Market Share Loss

Future U.S. share losses for Henry Schein’s consumables business are expected, predominantly to online solutions.

Stock Valuation Concern

Henry Schein's stock currently trades at a slight premium to its three-year average relative to the XLV, which is concerning given market share issues.

Henry Schein Business Overview & Revenue Model

Company Description

Henry Schein, Inc. is a leading global distributor of healthcare products and services to office-based dental and medical practitioners. The company operates in two main sectors: healthcare distribution and technology. It offers a comprehensive range of products, including dental supplies, medical supplies, and equipment, as well as value-added services such as practice management software solutions and consulting services. With a strong global presence and a focus on providing innovative solutions, Henry Schein supports healthcare professionals in delivering quality care to their patients.

How the Company Makes Money

Henry Schein makes money primarily through the distribution of healthcare products and services. The company's revenue model is built on selling dental and medical supplies, equipment, and pharmaceuticals to healthcare practitioners. A significant portion of its revenue comes from the sale of consumables and equipment in the dental and medical segments. Additionally, Henry Schein generates income from technology and value-added services, including practice management software, e-commerce solutions, and consulting services. Key revenue streams include direct sales to healthcare providers and partnerships with manufacturers and suppliers, which enable the company to offer a broad portfolio of products. The company's global reach and strong distribution network contribute significantly to its earnings by ensuring efficient and timely delivery of products to its customers.

Henry Schein Financial Statement Overview

Summary

Henry Schein shows stable financial health with consistent profitability, efficient cash flow management, and a balanced capital structure. While revenue growth is flat, strong cash generation and healthy margins support operational efficiency.

Income Statement

The company exhibits stable gross and net profit margins with a Gross Profit Margin of 31.1% and a Net Profit Margin of 3.2% for TTM. Revenue growth has plateaued recently, with a slight decline in TTM revenue compared to the previous year. EBIT and EBITDA margins remain healthy at 5.2% and 7.7%, respectively, indicating operational efficiency.

Balance Sheet

The Debt-to-Equity Ratio stands at 0.97, reflecting moderate leverage. The Return on Equity (ROE) is 12.3%, showcasing decent profitability on equity, though it has decreased over time. The Equity Ratio of 31.6% indicates a balanced approach to financing between debt and equity.

Cash Flow

The company demonstrates strong cash flow management with an Operating Cash Flow to Net Income Ratio of 1.69 for TTM, indicating robust cash generation from operations. Free Cash Flow has seen a decline in growth, but remains positive at $518 million, supporting operational and strategic initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.77B	12.67B	12.34B	12.65B	12.40B	10.12B
Gross Profit	3.94B	4.02B	3.86B	3.83B	3.67B	2.81B
EBITDA	961.00M	941.00M	877.00M	1.08B	1.07B	726.81M
Net Income	389.00M	390.00M	416.00M	538.00M	631.00M	403.79M
Balance Sheet
Total Assets	10.91B	10.22B	10.57B	8.61B	8.48B	7.77B
Cash, Cash Equivalents and Short-Term Investments	145.00M	122.00M	171.00M	117.00M	117.97M	421.19M
Total Debt	3.36B	2.87B	2.74B	1.50B	1.22B	1.00B
Total Liabilities	6.01B	5.38B	5.42B	3.94B	4.42B	3.79B
Stockholders Equity	3.44B	3.39B	3.65B	3.45B	3.43B	3.35B
Cash Flow
Free Cash Flow	358.00M	661.00M	313.00M	506.00M	630.57M	550.08M
Operating Cash Flow	512.00M	848.00M	500.00M	602.00M	709.58M	598.91M
Investing Cash Flow	-394.00M	-430.00M	-1.14B	-276.00M	-677.22M	-115.02M
Financing Cash Flow	-52.00M	-510.00M	701.00M	-315.00M	-332.96M	-187.19M

Henry Schein Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 64.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSIC, the sentiment is Negative. The current price of 64.83 is below the 20-day moving average (MA) of 70.57, below the 50-day MA of 71.40, and below the 200-day MA of 71.50, indicating a bearish trend. The MACD of -1.10 indicates Positive momentum. The RSI at 33.35 is Neutral, neither overbought nor oversold. The STOCH value of 22.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HSIC.

Henry Schein Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PDCO	70 Outperform	$2.77B	20.21	14.15%	―	-0.85%	-23.40%
MCK	69 Neutral	$88.62B	27.58	51.23%	0.40%	16.22%	15.29%
Sector *	65 Neutral	¥342.45B	8.70	-3.93%	2.47%	11.16%	-19.70%
CAH	63 Neutral	$37.77B	24.71	-43.80%	1.30%	0.78%	183.45%
HSIC	61 Neutral	$7.89B	20.85	11.18%	―	2.29%	14.98%
COR	58 Neutral	$56.66B	34.08	161.58%	0.74%	11.56%	5.31%
OMI	44 Neutral	$498.76M	―	-49.91%	―	2.84%	-828.91%

Henry Schein Corporate Events

Henry Schein CEO Stanley Bergman Announces Retirement

On July 15, 2025, Henry Schein announced that its long-serving CEO, Stanley M. Bergman, will retire at the end of the year after 45 years with the company, including over 35 years as CEO. Bergman will remain as Chairman of the Board, and the company has initiated a search for his successor. Under Bergman’s leadership, Henry Schein grew significantly, transforming from a small dental mail-order company into a global leader in healthcare solutions. The company’s revenue increased from $225 million in 1989 to nearly $13 billion in 2024, with a market capitalization approaching $9 billion. Bergman’s strategic vision and leadership have been pivotal in positioning Henry Schein as a key player in the healthcare industry.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.

Henry Schein Amends $750M Term Loan Agreement

On June 6, 2025, Henry Schein, Inc. amended and restated its existing $750 million term loan credit agreement and $1 billion revolving credit agreement. These amendments extend the termination date of the term loan to June 6, 2030, and modify certain financial definitions and covenants. The company plans to utilize these facilities for working capital, general corporate purposes, capital expenditures, stock repurchase, refinancing existing debt, and potential acquisitions. The agreements include customary representations, warranties, covenants, and events of default, impacting the company’s operational flexibility and financial strategies.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.

Henry Schein Approves Key Proposals at Annual Meeting

On May 22, 2025, Henry Schein, Inc. held its 2025 Annual Meeting of Stockholders where key proposals were approved, including the election of twelve directors for terms expiring in 2026, and the election of Max Lin and William K. ‘Dan’ Daniel as directors. The meeting also saw the approval of the 2024 compensation for Named Executive Officers and the ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 27, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.

Henry Schein Completes $250M Deal with KKR

On May 16, 2025, Henry Schein, Inc. completed a $250 million strategic investment deal with KKR, making KKR the holder of approximately 12% of Henry Schein’s common shares. This investment is part of a strategic partnership agreement that also led to the appointment of William K. ‘Dan’ Daniel to Henry Schein’s Board of Directors. Daniel, an Executive Advisor at KKR, brings over three decades of leadership experience in the industrial and healthcare sectors. His appointment, alongside Max Lin from KKR, is expected to support Henry Schein’s strategic growth and long-term value creation for stakeholders.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.